Inactivation of both PIM kinases and LKB1 results in a significant decrease in cell proliferation in vitro and tumor growth in vivo, suggesting that PIM-targeted pharmaceutical interventions could be exploited to suppress the growth of LKB1-deficient tumors. Here, PIM1 is linked to neoplasm.